EP. 1: BTK-Targeted Therapy for CLLByTargeted OncologyPublished: May 8th 2020 | Updated: April 27th 2021
EP. 2: Acalabrutinib Versus Ibrutinib for CLLByTargeted OncologyPublished: May 8th 2020 | Updated: April 27th 2021
EP. 3: Acalabrutinib Treatment Considerations in CLLByTargeted OncologyPublished: May 8th 2020 | Updated: April 27th 2021
EP. 4: Selecting Frontline Therapy for CLLByTargeted OncologyPublished: May 8th 2020 | Updated: April 27th 2021
EP. 5: MRD and 11q Deletions in CLLByTargeted OncologyPublished: May 8th 2020 | Updated: April 27th 2021
EP. 6: BTK Inhibitors for Elderly Patients With CLLByTargeted OncologyPublished: May 8th 2020 | Updated: April 27th 2021
EP. 7: Long-Term Experience With BTK Inhibitors for CLLByTargeted OncologyPublished: May 8th 2020 | Updated: April 27th 2021
EP. 8: Combination Therapies With BTK Targeted Therapy in CLLByTargeted OncologyPublished: May 8th 2020 | Updated: April 27th 2021
EP. 9: BTK Inhibition in CLL: Real-World DataByTargeted OncologyPublished: May 8th 2020 | Updated: April 27th 2021
EP. 10: Resistance to BTK Targeted Therapy in CLLByTargeted OncologyPublished: May 8th 2020 | Updated: April 27th 2021
EP. 11: Treating CLL With BTK Inhibition: Next StepsByTargeted OncologyPublished: May 8th 2020 | Updated: April 27th 2021
